Date: 2013-02-26
Type of information: Licensing agreement
Compound: deuterium-modified sodium oxybate (D-SXB) compounds, including C-10323
Company: Jazz Pharmaceuticals (Ireland) Concert Pharmaceuticals (USA - MA)
Therapeutic area: CNS diseases
Type agreement: development licensing commercialisation
Action mechanism: Sodium oxybate is the active ingredient in Xyrem®, a prescription medicine marketed in the United States by Jazz Pharmaceuticals to treat two of the key symptoms of narcolepsy.
Disease:
Details: * On February 26, 2013, Jazz Pharmaceuticals and Concert Pharmaceuticals announced an exclusive license agreement that provides Jazz Pharmaceuticals worldwide rights to develop and commercialize Concert’s deuterium-modified sodium oxybate (D-SXB) compounds, including C-10323. Under the agreement, Jazz Pharmaceuticals will have worldwide commercial rights to C-10323, as well as principal responsibility for ongoing development activities. Through Concert’s DCE Platform® (Deuterated Chemical Entity), Concert has developed a number of deuterium-containing analogs of sodium oxybate. C-10323 has emerged as the lead compound based on in vivo preclinical testing that demonstrated prolonged pharmacokinetic profile and reduced variability as a result of its specific deuterium modification pattern. The companies plan to submit an investigational new drug (IND) application for C-10323 later this year.
Financial terms: Concert will receive an upfront payment and is eligible to receive additional milestone payments as well as tiered royalties based on potential worldwide sales of any D-SXB products.
Latest news:
